What is Nozin® Nasal Sanitizer® advanced antiseptic?
Nozin® Nasal Sanitizer® Advanced Antiseptic is a non-prescription, patented product with demonstrated microbial killing activity that is topically applied with a swab to the skin at the opening (vestibule) of each nostril. The result of years of research, the patented Nasal Sanitizer® Nozaseptin® formula combines the safe, proven, antiseptic power of ethyl alcohol with the emollient, antioxidant benefits of natural oils. Nozin® Nasal Sanitizer® is well tolerated as it has a pleasant citrus scent, is gentle and highly moisturizing to the nasal opening, while maintaining potent antimicrobial activity. Unlike an antibiotic, Nasal Sanitizer® does not promote antibiotic resistance as it utilizes non-selective antiseptic action of ethanol.
This product is applied to the nasal vestibule, a critical site where pathogens colonize. After colonization of the nasal vestibule, pathogens can be transmitted, often by hand to nose contact, to others or to the skin where they can cause infections. Decolonization with Nozin® Nasal Sanitizer® decreases nasal bacteria carriage, helps maintain hand hygiene by lowering chance of nose to hand transmission and can help reduce the risk of infections.
In testing by independent FDA registered laboratories, Nasal Sanitizer® was shown on application in vitro to kill 99.99% of a broad spectrum of pathogenic organisms. Clinical studies show the product reduces harmful germs for up to 12 hours. Nozin® Nasal Sanitizer® has been shown to decrease nasal bacteria carriage.
Is Nozin® Nasal Sanitizer® safe for daily use?
Yes. Nozin® Nasal Sanitizer® is well tolerated as it has a pleasant citrus scent and is highly moisturizing to the skin at the nasal opening, while maintaining potent antimicrobial activity. The product complies with Food and Drug Administration regulations for over the counter (OTC) drugs as an antiseptic. Ethanol, the active ingredient in Nasal Sanitizer®, is classified as GRASE (generally recognized as safe and effective) when used as directed. It has been shown that alcohol based topical antiseptics can be less irritating than soap and water* and Nasal Sanitizer® has been specifically shown to be safe in dermal toxicity and skin irritation studies.
Unlike an antibiotic, the Nasal Sanitizer® preparation does not promote antibiotic resistance as it utilizes the non-selective antiseptic action of ethanol. Nasal Sanitizer® is used and recommended by many health professionals and their patients. Read the entire package prior to use.
What are the uses for Nozin® Nasal Sanitizer®?
Nozin® Nasal Sanitizer® is used as part of Nozin NOVA Programs for nasal colonization risk mitigation for your healthcare facility and hospital. A comprehensive implementation is best approached with the services of the Nozin NOVA programs in which experienced Nozin personnel can guide you in your implementation.
Learn about the Nozin NOVA™ Program and solutions for your facility.
Is there published, peer-reviewed research on Nozin® Nasal Sanitizer®?
Here's a link to a number of independent clinical study outcomes
The American Journal of Infection Control (AJIC) has published the article: “Reduction of nasal Staphylococcus aureus carriage in health care professionals by treatment with a nonantibiotic, alcohol-based nasal antiseptic”
Here's a link to AJIC website for the article on the clinical study which showed that Nozin® Nasal Sanitizer® antiseptic was effective in reducing Staph aureus and total bacterial carriage, ”suggesting the usefulness of this approach as a safe, effective and convenient alternative to antibiotic treatment.”
Also now available at the American Journal of Infection Control website is the article, "Perioperative participation of orthopedic patients and surgical staff in a nasal decolonization intervention to reduce Staphylococcus spp surgical site infections". Quoting from this study, which utilized Nozin® Surgery protocol with Nozin® Nasal Sanitizer® antiseptic: “After implementation of an alcohol-based antiseptic nasal decolonization program in patients and members of our hospital spine surgery group, Staphylococcus spp SSIs were significantly reduced from baseline over the subsequent 15-month period.” This study, conducted at Baylor Orthopedic and Spine Hospital at Arlington, TX, demonstrated 81% SSI reduction. An earlier phase of this Baylor study was well received as a poster at IDSA ID Week 2016. The article at AJIC is available for pdf download as published in an AJIC issue.
Is there independent research support for implementing nasal decolonization?
Yes. For an immediate overview to independent clinical study outcomes please click here. Nasal decolonization is an important topic which is covered in the whitepaper "Emerging Strategies on Achieving Nasal Decolonization for Reducing Hospital Acquired Infections" (link). Studies show that nasal carriage of pathogens can increase the risk of healthcare-associated infections and that hygiene protocols which include nasal decolonization can help reduce this risk. Nasal decolonization is now recognized at the forefront for infection control programs. Hand to nose contact occurs about every 4 minutes for everyone, often compromising hand hygiene and risking contamination. 80% of SSI pathogens’ DNA can be tracked to the patient’s own nose.
Should Health Care Workers (HCW) use Nozin Nasal Sanitizer®?
A number of factors support Nozin Nasal Sanitizer® use by HCWs. Studies show that substantial percentages of the population can carry pathogens in the nares. In addition, transient nasal inoculation by potential pathogens may occur through contact during the work day. All of these bacteria are then positioned for transfer to patients and other personnel.
As nose touching frequently compromises hand hygiene, Nasal Sanitizer® can be used to complement hand washing and hand sanitizer use. The application is pleasant, moisturizing and, importantly, bacteria will not build antibiotic resistance to this non-antibiotic product.
Why should non-surgical patients use Nozin® Nasal Sanitizer®?
Studies show that ~30% of the population has Staph aureus colonization in the nares and ~3% have MRSA. Providing patients upon admission with Nozin Nasal Sanitizer® can help reduce the risk of bringing these potential pathogens into the healthcare facility.
How would we implement Nozin NOVA programs in our facility/hospital?
The Nozin NOVA Team will fully support facilities as they go through the implementation process and assist in creating high-impact clinical protocols for nasal colonization risk mitigation.
In what presentations does the product come and how can I learn more?
How much does it cost?
For less than the cost of screening alone, you can effectively implement a decolonization program using Nozin® Nasal Sanitizer®. Contact your Nozin representative to review options for your facility.
Is Nozin® Nasal Sanitizer® antiseptic patented?
Yes. Nozin® Nasal Sanitizer® antiseptic is covered by the following granted U.S. Patents:
- U.S. Patent No. 8,778,415
- U.S. Patent No. 8,158,163
- U.S. Patent No. 7,638,147
- U.S. Patent No. 8,999,406
- U.S. Patent No. 9,463,212
- U.S. Patent No. 9,943,561
- U.S. Patent No. 10,307,452
Who makes Nozin products?
Global Life Technologies Corp. is the maker of Nozin® brand products including Nasal Sanitizer® and Allergy Master®. Located Miami, Florida and Bethesda, Maryland, this U.S. based company follows a mission to improve the quality of life for people by introducing unique and effective healthcare products based on innovative patented and patent pending technologies. Backed by years of research, supported by NIH grants and successful clinical trials, Nozin products are directed at growing health maintenance and infection prevention markets. Made in the USA, Nozin products have been well received by hospitals, doctors and healthcare professionals who use them and recommend them to patients.
MENU
